Formosa Pharmaceuticals News

Formosa Pharmaceuticals completes USD $21.1 million fundraising and increase in cash capital

April 16, 2021

Formosa Pharmaceuticals (FP), a subsidiary of Formosa Laboratories (TWSE 4746), has
successfully completed a Series C financing round, increasing its cash capital by NTD $600
million (approx. USD $21.1 million).

In addition to the continuous support from major shareholder, Formosa Laboratories, numerous
prominent venture capital firms participated in this round of capital increase, including China
Development Industrial Bank (CDIB), China Trust Bank Corporation (CTBC), Chailease Finance,
Industrial Technology Investment Corporation (ITIC), United Microelectronics Corp (UMC),
Savior Lifetec Corporation (SLC), Cathay Venture, Inc., Black Marble Capital Management, H&Q
Asia Pacific, and Concord Venture Capital Group.

The funds will primarily support United States-based Phase 3 clinical trials of APP13007, a novel
therapy for inflammation and pain after cataract surgery. Utilizing Formosa Pharma’s proprietary
nanoparticle formulation platform (APNT), APP13007 combines durable and potent efficacy with
a favorable safety profile which should offer patients a formidable treatment option. Formosa
Pharma anticipates receiving FDA approval in 2023 and partnering for global commercialization
in indications with market sizes well in excess of USD $1 billion dollars.

In addition, Formosa Pharma is co-developing TSY-0110, a biosimilar of antibody-drug conjugate
Kadcyla®, with EirGenix and Formosa Laboratories. Kadcyla®, approved for metastatic breast
cancer (2013) and early breast cancer (2019), is projected to have peak sales at USD $2.5 billion
dollars and is being explored actively in other HER2-driven indications both as a single-agent and
in combination with other therapies.

“With the confidence and recognition from shareholders and a formidable development team
including Formosa Laboratories, EirGenix, AimMax, and other strategic partners, Formosa
Pharma will continue to enhance its R&D capabilities and shareholders’ equity,” said by Dr. Erick
Co, Ph.D., Chief Executive Officer of Formosa Pharmaceuticals.

Formosa Pharmaceuticals, Inc.
Tel: +886-2-2755-7659
Email: ir@formosapharma.com

About Formosa Pharmaceuticals:
Formosa Pharmaceuticals, a subsidiary of Formosa Laboratories, was founded in 2010 and has
NTD $988 million (approx. USD $35 million) paid-in capital. Formosa Pharma is led by Dr.
Chen-Yu Cheng, Ph.D., Founder, Chairman, and President of both Formosa Laboratories and
Formosa Pharmaceuticals, and Dr. Erick Co, Ph.D., Chief Executive Officer.

Development Pipeline

Scroll to Top